 In this study, researchers have identified a protein called DDRGK1 as a key player in osteosarcoma chemoresistance. They found that higher levels of DDRGK1 are associated with more aggressive tumors and poorer survival rates. Additionally, they showed that DDRGK1 blocks the activity of a protein called KEAP1, which normally helps to protect against oxidative stress. This leads to increased levels of oxidative stress, which can cause cell death. Knocking out DDRGK1 in osteosarcoma cells caused them to be more sensitive to chemotherapy drugs such as doxorubicin. Finally, when combined with doxorubicin, the combination therapy was able to kill osteosarcoma cells in mice. This article was authored by AXIEN Wang, Tang Junzhu, Shaoyang, and others.